Patient Preferences and Treatment Decision Drivers in IDH-Mutant Grade 2 Glioma: An International Discrete Choice Experiment
{{output}}
Background: Grade 2 isocitrate dehydrogenase (IDH)-mutant (mIDH) glioma imposes significant health-related quality of life (HRQoL) and economic burden. Objective:... ...
